Clover Biopharmaceuticals announces the formation of the Global Scientific Advisory Board for the COVID-19 Vaccine Program

Clover Biopharmaceuticals, a global clinical biotechnology company aimed at the discovery and progression of vaccines and transformative biological treatments, announced the formation of its Scientific Advisory Council (SAB) of world-renowned experts in the vaccine industry, public aptitude and policy progress. provide strategic oversight and recommendations for the overall progression of S COVID-19 trimer clover protein vaccination programs.

Joshua Liang, CEO of Clover Biopharmaceuticals, said: We are honored to welcome leading vaccine experts to our new SAB. diversity of experiences, SAB will play a valuable role in advising Clover on all facets of our progression and access to the global vaccine in the critical months to come.

Ralf Clemens, MD, Ph. D. , president of SAB, added: I am pleased to lead this team of vaccine and immunization leaders with varied and complementary experience and decades of delight with Clover in his cutting-edge paintings with the COVID-19 S-Trimer Vaccine that employs its patented Trimer-Tag technology. All SAB members express Clovers’ vision of expanding and producing a safe, effective and available vaccine that can provide much-needed relief from communities around the world to involve this pandemic.

The Clovers COVID-19 S-Trimer vaccine was developed by combining the complex sarS-CoV-2 (S) trimric protein with exclusive Trimer-Tag technology. In preclinical studies, S-Trimer induced strong immune responses with fun moving mediation and Th1 in various animal and monkey models by provocation through SARS-CoV-2. The ongoing Phase 1 tribole clinical trial is a randomized, unansistant, placebo-controlled study of the safety, reactogenicity and immunogenicity of COVID-19 multi-dose S-Trimer Vaccine. The study completed the recruitment of 150 adult and elderly participants, and will recruit another 200 participants in the decided dose in a Phase 1 dose expansion exam. Clover concludes to publish a global study on the effectiveness of the vaccine Phase 2/3 of the vaccine until the end of 2020 The Clovers COVID-19 immunization program is supported through investment and collaboration with the Coalition for Innovations in Epidemic Preparedness (CEPI).

Clovers SAB is composed of the following members:

Ralf Clemens, MD, Ph. D. , president of SAB, former senior vice president/global director of vaccine development at Takeda, Novartis Vaccines and GSK; former board member of the International Vaccine Institute (IVI).

Donna Ambrosino, MD, research advisor, former ceo of Nosocomian Vaccine Corp; former executive director of MassBiologics and professor of pediatrics at the University of Massachusetts School of Medicine.

Sue Ann Costa Clemens, MD, Ph. D. , Clinical Development Advisor, Visiting Professor of Global Health, University of Oxford; Director of the Oxford-Brazil Vaccine Group; Professor and Director of the Institute of Global Health, Universita di Siena; Vice President of Vaccines (Latin America), GSK.

Pierre Desmons, Ph. D. , CMC advisor, former vice president, Director of I D of China and Director of Asia Strategic Partnerships, GSK.

Sam Liao, Strategy and Business Development Advisor, Former Head of Licensing and Business Development (Asia), Novartis Vaccines; former director of development, Sanofi.

Michael Pfleiderer, Ph. D. , Regulatory Affairs Advisor, Senior Consultant, Biopharmaceutical Excellence; former director of the viral vaccines section, Paul-Enrlich-Institut (PEI); Former President of the Pandemic Operation (2009/10), European Medicines Agency (EMA).

Peter Richmond, MBBS MCRP (UK) FRACP, Medical Advisor, Head of the Division of Pediatrics (Faculty of Health and Medical Sciences), University of Western Australia; Head of the Vaccine Testing Group, Telethon Kids Institute.

Antoinette Quinsaat, project management consultant, former head of clinical operations (international), GSK Biologicals and Novartis Vaccines; former study control director (Asia-Pacific), Sanofi.

Frank Rockhold, Ph. D. , Biostatistics Consultant, Professor of Biostatistics and Bioinformatics, Duke University Medical Center; Managing Partner, HunterRockhold Inc; Former GSK Senior Vice President and Chief Security Officer.

David Salisbury, public health adviser, former director of immunization, Department of Health (London); former chairman of the Strategic Advisory Group on Immunization, World Health Organization (WHO); former co-chair of the Pandemic Influenza Group, G7 Global Health Initiative.

George Siber, MD, research advisor, co-founder of Affinivax; former executive vice president and chief scientific officer of Wyeth Vaccines; associate professor of Medicine, Infectious Diseases, Harvard Medical School.

Nelson Teich, MD, MSc, Public Health Adviser, former Minister of Health, Brazil; Founder and former president of the Integrated Clinical Oncology Group (IIC) and the IIC Institute of Management, Education and Research.

Anh Wartel, M. D. , Clinical Development Advisor, Deputy Executive Director, International Vaccine Institute (IVI); former senior director of clinical R&D, regional medical expert and national medical director (Vietnam/Cambodia), Sanofi.

Nicholas Jackson, Ph. D. , SAB Observer, Program and Innovation Officer, CEPI; former vice president and head of research at Sanofi.

Clover Biopharmaceuticals Clover Biopharmaceuticals is a global clinical stage biogeneration company based on research that aims at the discovery, progression and commercialization of transformative biological therapies, with a focus on oncology and autoimmune diseases, as well as viral vaccines. It has raised more than US$200. million in total capital since 2016, Clover is using its patented Trimer-Tag generation platform to expand new biological products targeting trimerization-dependent pathways. In addition, Clover leverages its internal GMP bioproduction functions for the large-scale production of its biological therapies. more information, visit our website: www. cloverbiopharma. com.

Using Clovers’ patented Trimer-Tag technology, S-Trimer is a candidate for SARS-CoV-2 subassing trimer (S) vaccine. Similar to other wrapped RNA viruses such as HIV, RSV and influenza, SARS-CoV-2 is also a RNA virus that has a high-tech trite protein (S) in its viral envelope. SarS-CoV-2 S-trimer protein is guilty of binding to the surface receptor of the ACE2 host’s mobile and the next viral entry, making it the number one antigen target for vaccine development. S-Trimer resembles the protein of the local triteric viral complex and an immediate expression formula based on a mobile mammal culture is produced.

In addition to the Trimer-Tag Trimer-Tag generation, trimer-Tag is a state-of-the-art drug progression platform that allows the production of new fusion proteins that are cut by covalence. Many primary disease targets feature triflation, such as the superfamily of tumor necrosis. (TNF) (involved in extrinsic apoptosis, immune costimulation and inflammation), as well as viral RNA antigens convicted of entering host cells. Clover uses its Trimer-Tag generation with a global IP position to expand recombinant trimeste fusion proteins that can target those on the indrugible pathways of the past well.

TIE’s Innovation Pilot Pavilion Showcases Government Agencies’ R&D Capabilities and Taiwan’s Smart Value

Digimind opens up a workplace in Amsterdam to the growth of northern Europe

NEW YORK, 25 September 2020 / PRNewswire / – Color Star Technology Co. , Ltd. (Nasdaq CM: HHT) (the “Company” or “Color Star”), a company dedicated to wisdom activities paid online and offline for the world media, entertainment and culture industries, today announced the update of its Color World app with an interactive live video streaming feature on October 15, 2020.

“We are very pleased with the upcoming update that adds an interactive live streaming feature (the ‘new feature’) to our very popular Color World app that gained tens and thousands of users after the official release of its Chinese edition on September 10, 2020. With the new feature, we plan to sponsor more live interactive events, such as virtual celebrity gatherings with fans, interactive educational courses, live concerts, and more. As we are committed to providing users with reports for our live events, we are also accelerating the progression of augmented truth (“AR”) features for the Color World app,” said Luke Lu, President and CEO of Color Star.

“While we’re bringing more musicians, actors and artists to our platform, which in turn attracts more fans, subscribers and paid users to our platform, the new feature is about to take our user engagement to another point in the future,” he concluded. Mr. Lee.

About Color Star Technology

Color Star Technology Co, Ltd. (Nasdaq CM: HHT) provides paid online and offline wisdom for the media, entertainment and culture industries around the world. Its business activities are carried out through its wholly owned subsidiaries Color China Entertainment Ltd. and CACM Group NY, Inc. La’s online education technology is provided through its Color World music education and entertainment platform. The company also offers after-school entertainment categories in New York City through its joint venture Baytao LLC. You can find more information about the company at www. colorstarinternational. com.

Forward-looking statement

This press release comprises forward-looking statements as explained through the Private Securities Litigation Reform Act of 1995. Forward-looking statements come with statements regarding long-term plans, objectives, goals, methods, occasions or functionality, as well as the underlying assumptions. and other statements that are not statements of ancient fact. When the company uses words such as “may”, “will”, “pretend”, “should”, “believe”, “expect”, “anticipate”, “plan”, “estimate” or similar words that are not related only to old business, makes forward-looking statements. More specifically, statements through the corporation related to the proposed acquisition of FENT are forward-looking statements. Forward-looking statements are not promises of long-term functionality and involve dangers and uncertainties that may cause actual effects to differ materially from corporate expectations described in the forward-looking statements. These statements are subject to uncertainties and dangers, including, but not limited to, the following: the objectives and methods of the company; the long-term progression of the company’s business; request and acceptance of products and facilities; technological changes; economic situations; expanding the market position of school and school facilities in China and other countries where HHT operates; reputation and brand; they have an effect on the festival and prices; government regulations; fluctuations in general economic and commercial situations and assumptions underlying or similar to any of the above and other dangers contained in the reports filed through the Company with the Securities and Exchange Commission. For these and other reasons, investors are cautioned not to place undue reliance on the forward-looking statements contained in this press release. Other points are discussed in documents filed through the Company with the United States Securities and Exchange Commission, which can be consulted at www. sec. gov. The Company assumes no legal responsibility to publicly review such forward-looking statements to reflect occasions or events that occur after the date hereof.

For more information, please contact:

Tony Tian, CFA Email: [email protected] Phone: 1-732-910-9692

Related links:

https://www. colorstarinternational. com/

LISHUI, China, 25 September 2020 / PRNewswire / – Farmmi, Inc. (“Farmmi” or “Company”) (NASDAQ: FAMI), a supplier of agricultural products in China, announced that it will provide corporate services and subsequent agricultural products at SIAL China (www. sialchina. com) from September 28 to 30, 2020. SIAL China is Asia’s largest food innovation fair and will be held at the Shanghai National Exhibition and Convention Center.

Known as China’s ultimate vital occasion for the food and beverage industry, SIAL China promotes direct industry relationships with other import/distribution segments in China and Asia, adding supermarkets/hypermarkets, wholesalers, catering (hotel/restaurant) and importers/commercial agents. China is an integral component of the SIAL network, the world’s largest food and beverage fair network. The screen sets the benchmark for corporations built in Asia and China, and provides valuable data on the market, trends and inventions of the regional food industry. . SIAL China was originally scheduled for May 2020, but was postponed due to considerations on COVID-19 and its effect on participants.

Yefang Zhang, President and CEO of Farmmi, said: “We are very excited and willing to engage with strategic partners and consumers face-to-face in this vital exhibition, now in its twentieth year. Nothing can update our green, eco-healthy and friendly brands of dried mushrooms, black mushrooms and other edible mushroom products and skills, along with more than 2,200 exhibitors expected to stop at the 60,000 business points expected from China and major foreign markets. “

Ms. Zhang continued: “While others aspire to a higher quality of life and seek a superior quality of life, Farmmi meets the demands of the customer market and actively creates a new way to track the quality and protection of its entire business chain. At the same time, Farmmi is the source of capacity for green, organic and high quality agricultural products, while strengthening the competitiveness of agricultural products in the market. “

About Farmmi, Inc.

Farmmi, Inc. (NASDAQ: FAMI), headquartered in Lishui, Zhejiang, is a leading supplier, processor and warehouse of shiitake mushrooms, Mu Er mushrooms, other edible fungi and many other coveted agricultural products. The company’s Farmmi Liangpin market serves as an advertising platform for geographically indicated Chinese agricultural products and provides a giant platform for consumers to access home agricultural products. For more information about the company, visit: http://ir. farmmi. com. cn/.

Forward-looking statements

This announcement comprises forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of prior fact in this announcement are forward-looking statements, adding that forward-looking COVID -19 has an effect on our activities in China and abroad. These forward-looking statements involve known and unknown dangers and uncertainties and are based on existing expectations and projections related to long-term occasions and monetary trends that the Company believes may also only be its monetary condition, effects of operations, business strategy. and your monetary needs. Investors would possibly identify such forward-looking statements through words or words such as “possibly”, “will”, “expect”, “anticipate”, “aim”, “estimate”, “intend”, “plan”, “believe”, “prospective”, “continues”, “is / is more likely than” or other similar expressions. The Company assumes no legal responsibility to update forward-looking statements to reflect upcoming occasions or circumstances, or adjustments to your expectations, unless as required by law. While the company believes that the expectations expressed in those forward-looking statements are reasonable, it cannot guarantee that those expectations will turn out to be correct, and the company cautions investors that actual effects may differ materially from expected effects.

Leave a Comment Cancel Reply